Subscribe to Newsletter
Business & Profession Professional Development

Valeant Stalks Allergan

What might “ValGan” look like in six months’ time? Considerably leaner. Valeant’s CEO, J. Michael Pearson, highlighted plans for extensive executive and administrative layoffs if the takeover is successful. “These are not people touching the customers,” Pearson said, “They are people sitting in offices, and we don’t need people sitting in offices.” Pearson anticipates that 80 percent of the cuts would occur within the first six months after the deal, a process that is predicted to generate $2.7bn in cost savings.

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: